Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Breast Cancer|Metastatic Melanoma|Non-small Cell Lung Cancer (NSCLC)
Interventions: DRUG: F16IL2 in combination with paclitaxel
Sponsor: Philogen S.p.A.